Back HIV/AIDS HIV/AIDS Topics HIV Prevention Injection Drug Use NHPC 2015: U.S. Syringe Funding Ban Impedes HIV and Hepatitis C Prevention

NHPC 2015: U.S. Syringe Funding Ban Impedes HIV and Hepatitis C Prevention

alt

Providing sterile syringes is a proven effective method for preventing HIV and hepatitis C virus (HCV) infections among people who inject drugs, yet the U.S. government continues to prohibit use of federal funds for this purpose, presenters said at the 2015 National HIV Prevention Conference (NHPC) last week in Atlanta. A federal budget bill now under consideration could lift the funding ban on syringe exchange programs. 

[Editor's note: The budget bill passed soon after the conference included language that allows cities and states to use federal money to support syringe exchange program expenses other than purchasing syringes.]

The Centers for Disease Control and Prevention's "high-impact prevention" initiative aims to target the right combinations of scientifically proven, cost-effective, and scalable interventions to the right people, at the right time, and in the right geographic areas -- and syringe exchange and distribution programs have been shown to fill that role for injection drug users.

 

Syringe distribution is "cost-effective and cost-saving," Jonathan Mermin, director of CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, said in his plenary talk on high-impact prevention.

"We must address the needs of people who inject drugs and in particular the opioid epidemic," added Murray Penner, executive director of theNational Alliance of State and Territorial AIDS Directors, during a panel discussion following Mermin's talk. "We must end the congressional ban on use of federal funds for syringe access programs."

As previously reported, in early 2015 public health officials detected an outbreak of new HIV infections associated with injection of prescription opioids, particularly oxymorphone, in rural Scott County, Indiana (May 1, 2015 Morbidity and Mortality Weekly Report) In March the state governor declared a public health emergency allowing local authorities to establish syringe exchanges.

At the International AIDS Society conference this summer John Brooks from the CDC's HIV Epidemiology Team described efforts to determine the source of the outbreak, halt further infections, and bring affected people into care. At IDWeek 2015 researchers reported that an emergency syringe program in Scott County led to a decrease in high-risk behaviors including needle sharing over its first 5 months.

SEPs Reduce Injection Risk

Dita Broz from the CDC and colleagues analyzed data from the 2012 National HIV Behavioral Surveillance system, looking at self-reported HIV risk behaviors among more than 10,000 people who inject drugs in U.S. 20 cities with and without large-scale syringe exchange programs (SEPs) that distribute more than 55,000 syringes annually.

They found that injection drug users living in cities with large-scale SEPs (about 70% of survey participants) were less likely than those in cities without such programs to engage in high-risk injecting behaviors, including being more likely to obtain sterile syringes, less likely to inject with used syringes, and less likely to share syringes with more than 2 people; they were also more likely to accept free condoms. While two-third of drug injectors obtained syringes from SEPs in cities with large-scale programs, fewer than 20% did so in cities without such programs.

A related analysis found that while only half of injection drug users participating in the survey were recently tested for HIV, testing was more common among people who accessed health and HIV prevention services such as syringe exchanges.

"Together with past and current research on effectiveness of SEPs in reducing injection-related HIV transmission, these findings support the utility of SEPs as important HIV prevention tools in large urban centers in the United States," the researchers concluded.

Veteran PWID HIV researcher Don Des Jarlais from Mount Sinai Beth Israel Medical Center presented findings from an analysis looking at the prospects for ending HIV epidemics among people who inject drugs in a high-resource setting (New York City) and a resource-limited setting (Haiphong, Vietnam).

Both cities have implemented combined prevention interventions including syringe programs, opiate substitution treatment, and antiretroviral therapy (ART) for HIV-positive people (available to all in New York City and those with a CD4 count above 350 cells/mm3 in Haiphong). Syringe distribution occurs primarily through SEPs in New York and pharmacy sales in Haiphong.

They found that HIV prevalence among injection drug users in New York City declined from 50% in 1990 to 6% currently, with 76% of HIV-positive PWID currently on ART. In Haiphong prevalence declined from 66% in 2006 to 25% currently, with 34% of HIV-positives on ART. Estimated HIV incidence rates are 0.1 and 2.0 new infections per 100 person-years in New York and Haiphong, respectively.

The researchers concluded that the HIV among people who inject drugs in New York "has reached an 'end of the epidemic' low incidence stage" (defined as >0.5 per 100 person-years), with Haiphong running approximately 10-15 years behind.

Ending the Syringe Funding Ban

Mary Beth Levinfrom Georgetown University School of Medicine and Bill McColl of AIDS United discussed ending the U.S. federal funding ban on syringe programs in a session on "Advancing HIV and Hepatitis Prevention for Drug Users." Levin explained that the ban -- first implemented more than 20 years ago -- was lifted in 2009, but reinstated by Congress in 2011.

According to Levin, 8% of new HIV infections -- or 11 per day -- are attributable to sharing drug injection equipment, with a disproportionate number of cases occurring among African Americans and Latinos. Studies indicate that sterile syringe availability has reduced HIV among people who inject drugs by 80% -- second only to the success of using antiretrovirals to prevent mother-to-child HIV transmission.

Lifting the federal funding ban would cost nothing in and of itself -- it would simply allow local and state governments to use existing funds to cover syringe programs. Experts estimate that every $1 spent on syringe programs would lead to $7 in savings on HIV treatment costs, with the biggest savings accruing to Medicaid and Medicare.

In addition to preventing HIV and HCV infections, syringe exchanges can also serve as a bridge to bring people into substance use treatment and the broader healthcare system, and can encourage safe disposal of used syringes as users return them to the program.

"It is a myth that syringe exchange is controversial," Levin said, noting that such programs currently exist in more than 30 states. "There is widespread local acceptance -- everyone else is on board except for the feds."

McColl said that nearly half of all syringes distributed through existing programs are paid for by the Syringe Access Fund, which will soon lose a substantial portion of its funding.

"Private funding alone cannot by itself solve the issue of syringe access for people who inject drugs," McColl stressed. "It is unacceptable that people think that's how it should be done."

Levin and McColl explained that the federal omnibus budget bill currently under consideration includes consensus House and Senate language that would allow funding for syringe access programs in areas where there is a risk of HIV and HCV outbreaks. They encouraged conference attendees to contact their representatives to urge its passage.

"By becoming legal we gain financial stability and the ability to do more data and evaluation," Laura Thomas of the Drug Policy Alliance said during a roundtable discussion of harm reduction advocates. "Supervised injection facilities are the next place we're going to go."

Legalized pharmacy sales are also an important component. "Even if every county had a syringe exchange, that would not be enough," said Alessandra Rossof the California Department of Public Health. "Pharmacies are there, they're open at 2 a.m., and pharmacies are going to support a lot of people in a lot of areas."

Several speakers at the conference noted that the Indiana outbreak has called attention to the risk of injection-related HIV and hepatitis C beyond the stereotypical urban communities of color and provides an opportunity to push for policy change -- but the window may be brief.

"Our secret weapon is quiet white suburban parents, grandmas, and law enforcement officers," said Mona Bennett of the Atlanta Harm Reduction Coalition.

The CDC estimates that at least 200 communities in 26 states are vulnerable to injection-related HIV and HCV outbreaks like the one in Indiana, CDC director Thomas Frieden said in his closing talk at the conference, emphasizing, "We must make syringe exchange available where it's not available."

12/15/15

References

D Broz, M Spiller, C Wejnert, et al. HIV Risk Behaviors and Prevention Services among Persons who Inject Drugs in 20 cities with and without Large-Scale Syringe Exchange Programs in the United States. National HIV Prevention Conference. Atlanta, December 6-9, 2015. Abstract 1657.

L Cooley, C Wejnert, M Spiller, et al. Low HIV Testing Prevalence among Persons Who Inject Drugs -- National HIV Behavioral Surveillance, 20 U.S. Cities, 2012. National HIV Prevention Conference. Atlanta, December 6-9, 2015. Abstract 1520.

D Des Jarlais, K Arasteh, C McKnight, et al. Prospects for "Ending the HIV Epidemics" among Persons Who Inject Drugs in a High Resource Setting (NYC) and a Resource-Limited Setting (Haiphong, Viet Nam). National HIV Prevention Conference. Atlanta, December 6-9, 2015. Abstract 1857.

B Combs. Emergency Implementation of A Syringe Exchange Program During a Community Outbreak of HIV Infection Linked to Injection Drug Use -- Indiana, 2015. National HIV Prevention Conference. Atlanta, December 6-9, 2015. Abstract 5080.

MB Levin and B McColl. Ending the Ban on Federal Funding for Syringe Service Programs: New Environments, New Data, New Messages, New Messengers. National HIV Prevention Conference. Atlanta, December 6-9, 2015. Abstract 2034.